弥漫性大B细胞淋巴瘤患者中吲哚胺2,3-双加氧酶的表达及血清犬尿氨酸浓度 - Suppr

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

作者信息

Ninomiya Soranobu, Hara Takeshi, Tsurumi Hisashi, Goto Naoe, Saito Kuniaki, Seishima Mitsuru, Takami Tsuyoshi, Moriwaki Hisataka

机构信息

First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.

出版信息

Leuk Lymphoma. 2012 Jun;53(6):1143-5. doi: 10.3109/10428194.2011.643472. Epub 2012 Jan 11.

DOI:10.3109/10428194.2011.643472

PMID:22112045

Abstract

摘要

相似文献

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

Leuk Lymphoma. 2012 Jun;53(6):1143-5. doi: 10.3109/10428194.2011.643472. Epub 2012 Jan 11.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.

Eur J Haematol. 2010 Apr;84(4):304-9. doi: 10.1111/j.1600-0609.2009.01393.x. Epub 2009 Nov 7.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.

Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.

Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.

An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Leuk Lymphoma. 2016 Aug;57(8):1956-60. doi: 10.3109/10428194.2015.1117610. Epub 2016 Jan 4.

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Ann Hematol. 2011 Apr;90(4):409-16. doi: 10.1007/s00277-010-1093-z. Epub 2010 Oct 12.

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.

Leuk Lymphoma. 2012 Nov;53(11):2290-2. doi: 10.3109/10428194.2012.682311. Epub 2012 May 22.

Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.

Leuk Lymphoma. 2013 Nov;54(11):2441-7. doi: 10.3109/10428194.2013.780654. Epub 2013 Apr 17.

New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.

Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8.

引用本文的文献

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.

Cell Death Dis. 2022 Jun 27;13(6):572. doi: 10.1038/s41419-022-05021-2.

Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation.

Front Immunol. 2022 Mar 18;13:832263. doi: 10.3389/fimmu.2022.832263. eCollection 2022.

Clinical significance of oxidative stress for untreated patients with diffuse large B-cell lymphoma.

Mol Clin Oncol. 2022 Jan;16(1):4. doi: 10.3892/mco.2021.2437. Epub 2021 Nov 4.

Viability of diffuse large B-cell lymphoma cells is regulated by kynurenine 3-monooxygenase activity.

Oncol Lett. 2021 Nov;22(5):790. doi: 10.3892/ol.2021.13051. Epub 2021 Sep 17.

IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.

Cancers (Basel). 2021 Apr 15;13(8):1899. doi: 10.3390/cancers13081899.

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Cell Mol Immunol. 2021 May;18(5):1085-1095. doi: 10.1038/s41423-021-00655-2. Epub 2021 Mar 30.

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience.

Diagnostics (Basel). 2020 May 2;10(5):275. doi: 10.3390/diagnostics10050275.

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Front Immunol. 2018 Jul 11;9:1598. doi: 10.3389/fimmu.2018.01598. eCollection 2018.

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.

The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.

PLoS One. 2016 Jan 4;11(1):e0146279. doi: 10.1371/journal.pone.0146279. eCollection 2016.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

作者信息

Ninomiya Soranobu, Hara Takeshi, Tsurumi Hisashi, Goto Naoe, Saito Kuniaki, Seishima Mitsuru, Takami Tsuyoshi, Moriwaki Hisataka

机构信息

First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.

出版信息

Leuk Lymphoma. 2012 Jun;53(6):1143-5. doi: 10.3109/10428194.2011.643472. Epub 2012 Jan 11.

DOI:10.3109/10428194.2011.643472

PMID:22112045

Abstract

摘要

相似文献

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

Leuk Lymphoma. 2012 Jun;53(6):1143-5. doi: 10.3109/10428194.2011.643472. Epub 2012 Jan 11.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.

Eur J Haematol. 2010 Apr;84(4):304-9. doi: 10.1111/j.1600-0609.2009.01393.x. Epub 2009 Nov 7.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.

Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.

Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.

Leuk Lymphoma. 2016 Aug;57(8):1956-60. doi: 10.3109/10428194.2015.1117610. Epub 2016 Jan 4.

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Ann Hematol. 2011 Apr;90(4):409-16. doi: 10.1007/s00277-010-1093-z. Epub 2010 Oct 12.

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.

Leuk Lymphoma. 2012 Nov;53(11):2290-2. doi: 10.3109/10428194.2012.682311. Epub 2012 May 22.

Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.

Leuk Lymphoma. 2013 Nov;54(11):2441-7. doi: 10.3109/10428194.2013.780654. Epub 2013 Apr 17.

New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.

Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8.

引用本文的文献

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.

Cell Death Dis. 2022 Jun 27;13(6):572. doi: 10.1038/s41419-022-05021-2.

Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation.

Front Immunol. 2022 Mar 18;13:832263. doi: 10.3389/fimmu.2022.832263. eCollection 2022.

Clinical significance of oxidative stress for untreated patients with diffuse large B-cell lymphoma.

Mol Clin Oncol. 2022 Jan;16(1):4. doi: 10.3892/mco.2021.2437. Epub 2021 Nov 4.

Viability of diffuse large B-cell lymphoma cells is regulated by kynurenine 3-monooxygenase activity.

Oncol Lett. 2021 Nov;22(5):790. doi: 10.3892/ol.2021.13051. Epub 2021 Sep 17.

IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.

Cancers (Basel). 2021 Apr 15;13(8):1899. doi: 10.3390/cancers13081899.

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Cell Mol Immunol. 2021 May;18(5):1085-1095. doi: 10.1038/s41423-021-00655-2. Epub 2021 Mar 30.

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience.

Diagnostics (Basel). 2020 May 2;10(5):275. doi: 10.3390/diagnostics10050275.

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Front Immunol. 2018 Jul 11;9:1598. doi: 10.3389/fimmu.2018.01598. eCollection 2018.

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.

The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.

PLoS One. 2016 Jan 4;11(1):e0146279. doi: 10.1371/journal.pone.0146279. eCollection 2016.

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献